ROIV vs. TEM: Roivant Sciences vs. Tempus AI Stock Comparison

November 11, 2026

How do Roivant Sciences (ROIV) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Roivant Sciences (ROIV) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ROIV is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Company profile comparison for Roivant Sciences (ROIV) and Tempus AI (TEM)
Profile Item	ROIV	TEM
Name	Roivant Sciences Ltd.	Tempus AI Inc Class A Common Stock
Country/Region	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	28.08 billion USD	13.87 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	December 8, 2020	June 14, 2024
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ROIV

TEM

GSPC

Roivant Sciences (ROIV) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Roivant Sciences (ROIV) and Tempus AI (TEM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Roivant Sciences (ROIV) and Tempus AI (TEM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Total Return (1Y)	96.75%	16.25%
Total Return (3Y, Annualized)	68.04%	--
Total Return (5Y, Annualized)	36.73%	--

Risk Profile

Drawdown History

ROIV

TEM

GSPC

Roivant Sciences (ROIV) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Roivant Sciences (ROIV) and Tempus AI (TEM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Roivant Sciences (ROIV) is closer to market-like at 1.17 — a noticeable difference in market-sensitivity profile.

Risk profile metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Volatility (1Y, Annualized)	47.99%	76.08%
Beta (5Y)	1.17	3.34
Max Drawdown (5Y)	-79.22%	-59.76%
Avg. Volume (3M)	7.82M	7.20M

Risk-Adjusted Performance

Risk-Return Positioning

ROIV and TEM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Sharpe Ratio (1Y)	1.93	0.16
Sortino Ratio (1Y)	4.03	0.26

Profitability

ROE (TTM)

Both Roivant Sciences (ROIV) at -8.52% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-37.55%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
TEM: -37.55%
Q1: -64.05%
Min: -167.77%

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Roivant Sciences (ROIV) reports 0.00%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.54%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
TEM: -12.54%
Min: -17.05%

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Roivant Sciences (ROIV) at -25,408.11% and Tempus AI (TEM) at -13.82% report negative operating margin values, usually indicating operating losses over the period.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-13.82%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
TEM: -13.82%
Q1: -78.82%
Min: -207.40%

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
ROE (TTM)	-8.52%	-37.55%
ROA (TTM)	-16.28%	-7.36%
Net Margin (TTM)	0.00%	-12.54%
Operating Margin (TTM)	-25,408.11%	-13.82%
Gross Margin (TTM)	0.00%	64.46%

Growth

Revenue Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Roivant Sciences (ROIV) at -71.57% is in the bottom quartile, showing a clear gap in revenue momentum.

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Roivant Sciences (ROIV) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Revenue Growth (YoY)	-71.57%	83.41%
Revenue Growth (3Y CAGR)	-36.01%	58.29%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.61

Max: 25.13
Q3: 12.13
Median: 5.52
TEM: 2.61
Q1: 2.47
Min: 0.10

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Roivant Sciences (ROIV) at 0.02 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

TEM: 2.86
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Current Ratio (MRQ)	16.72	2.61
Debt / Equity (MRQ)	0.02	2.86
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Roivant Sciences (ROIV) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Roivant Sciences (ROIV) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Roivant Sciences (ROIV) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
TEM: --

Roivant Sciences (ROIV) vs. Tempus AI (TEM): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Tempus AI (TEM) at 9.19 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.19

Max: 58.18
Q3: 25.77
TEM: 9.19
Median: 7.30
Q1: 3.01
Min: 0.01

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Roivant Sciences (ROIV) at 6.64 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.66

TEM: 27.66
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Roivant Sciences (ROIV) vs. Tempus AI (TEM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Roivant Sciences (ROIV) and Tempus AI (TEM)
Metric	ROIV	TEM
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	3,728.61	9.19
P/B Ratio (MRQ)	6.64	27.66
Free Cash Flow Yield (TTM)	-3.98%	0.30%